Tech Company Financing Transactions
Curemark Funding Round
Private investors invested in a $18.5 million funding round for Curemark. This venture round was announced on 10/10/2013.
Transaction Overview
Company Name
Announced On
10/10/2013
Transaction Type
Venture Equity
Amount
$18,500,000
Round
Undisclosed
Investors
Proceeds Purpose
Curemark will use the funds for the completion and filing requirements for its New Drug Application (NDA) for CM-AT, the company's autism treatment, and the development of the other therapies in its pipeline.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
411 Theodore Fremd Ave. 206
Rye, NY 10580
USA
Rye, NY 10580
USA
Phone
Website
Email Address
Overview
Curemark is a socially driven biotechnology company focused on the treatment of Autism and other neurological diseases. The company is committed to improving the quality of life for children and adults with neurological disorders by providing safe, effective and clinically proven solutions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Joan Fallon
Chief Medical Officer
William Gannon
Chief Operating Officer
Jzaneen Lalani
VP - R & D
Matthew Heil
Browse more venture capital transactions:
Prev: 10/10/2013: Achvr venture capital transaction
Next: 10/10/2013: KinematIQ venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on tech company VC transactions. All VC database entries on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs